Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lacutoclax in Relapsed or Refractory CLL/SLL
NCT07609823Phase 2
Key facts
- Status
- Recruiting
- Start
- Jul 2026
- Primary completion
- Mar 2028
- Countries
- 1
- Sponsor
- Lupeng Pharmaceutical
- Drugs
- lacutoclax
- Conditions
- chronic lymphocytic leukemia (CLL)small lymphocytic lymphoma (SLL)
01
Overview
Phase 2, open-label, single-arm trial of lacutoclax in chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL), sponsored by Lupeng Pharmaceutical. Primary endpoint: Overall Response Rate assessed by Independent Review Committee. Started Jul 2026; status: recruiting.
02
Design
1 arm- Study design
- Non-randomizedOpen-labelSingle group
Lacutoclax
All participants will receive oral Lacutoclax tablets once daily with dose escalation to a target dose of 400 mg.
03
Who it enrols
Adult patients with relapsed/refractory CLL/SLL who have progressed after prior standard therapy, with measurable disease, ECOG <=2, and adequate organ function. Excludes patients with prior BCL-2 inhibitor treatment, Richter's syndrome, CNS involvement, or recent stem cell transplant/CAR-T therapy.
04
Endpoints
Primary
Overall Response Rate assessed by Independent Review Committee
Secondary
Overall Response Rate assessed by Investigator
Complete response plus complete response with incomplete bone marrow recovery rate
Time to response
Duration of response
Time to first 50% reduction in absolute lymphocyte count or normalization of ALC
Progression-free survival
Overall Survival
Adverse events
Beyond the preview
Go deeper on NCT07609823.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07609823.